Hemoglobin.

Ascorbate strongly improves non-heme iron uptake by reducing ferric to ferrous iron and chelating it past inhibitors. Heme iron enters through a different route, absorbed as the intact porphyrin complex, so ascorbate adds little to it. Pairing them is still reasonable in a mixed-iron formula, but the benefit lands on the non-heme fraction.

Calcium is the one dietary factor that interferes with both heme and non-heme iron absorption, which is unusual since most inhibitors touch only non-heme iron. The practical consequence is to separate a calcium dose from an iron dose by a couple of hours. Trial data in pregnancy has examined calcium supplementation alongside iron status measures.

Tea and coffee polyphenols bind non-heme iron in the gut lumen and sharply reduce its uptake. Heme iron is largely shielded from that binding because the iron sits coordinated inside the porphyrin ring. This is the main reason heme sources behave differently from iron salts at the same meal.

Iron cannot be loaded onto transferrin until it is oxidised by the copper-dependent ferroxidases hephaestin and ceruloplasmin. Low copper status therefore strands iron inside enterocytes and macrophages regardless of intake. Long-term high-dose iron or zinc can itself depress copper status, which makes this worth watching rather than ignoring.

Iron supplies the metal for the heme ring while B12 and folate supply the DNA synthesis capacity red cell precursors need to divide. A shortfall in either limits red cell production by a different route, and the resulting cell size runs in opposite directions. Correcting only one leaves the other as the limiting step.

Folate supports the thymidylate synthesis that dividing erythroid precursors depend on, which is why iron and folic acid are combined in most public health supplementation programmes. Comparative trial work has tested multiple micronutrient formulations against iron with folic acid. The two nutrients address different bottlenecks in the same production line.

The first committed step of heme synthesis, condensing glycine with succinyl-CoA, requires pyridoxal 5-phosphate. Without it, iron has no ring to be incorporated into. This dependence is the basis of the sideroblastic picture seen in severe B6 shortfall.

Vitamin A status influences the release of stored iron and its availability to erythropoiesis, which is why low retinol status blunts the response to iron supplementation in some populations. The mechanism runs through iron mobilisation rather than gut absorption. This matters mainly where both deficiencies coexist.

Riboflavin-derived flavins participate in the reduction of ferritin-bound iron for release, and correcting riboflavin status has been described as improving the response to iron. The evidence base is older and smaller than for the other B vitamins here. Read it as a supporting cofactor relationship rather than a headline pairing.

Zinc and non-heme iron compete at DMT1 and related divalent metal handling when given together in solution on an empty stomach. Heme iron uses a separate uptake route, so it is less affected by that competition. Splitting the doses across the day removes the issue either way.

Heme iron material and an iron salt both raise total iron intake, and they arrive by different absorption routes, so the doses stack. Hepcidin rises for roughly a day after a substantial iron dose and suppresses further absorption, which is why alternate-day or single-daily dosing is now studied so heavily. Combining sources without accounting for total intake risks overshooting.

Phytate from grains and legumes binds non-heme iron and is one of the strongest dietary inhibitors of its absorption. Phytase degrades it, freeing that iron fraction. Heme iron is again mostly insulated from the effect, so the benefit is specific to the non-heme portion of a mixed formula.